• Leviathan Natural Products (EPIC) has sold its 100-per-cent interest in Woodstock Biomed Inc. for $5,000,000
  • Proceeds from the sale will be used for general corporate purposes and working capital needs
  • Woodstock Biomed Inc. operates as a pharmaceutical company with a special focus on the production of medical cannabis for clients across Canada
  • In addition, the board of directors of Leviathan has appointed Linda Marabeti Romano as chief financial officer
  • Leviathan Natural Products Inc. is a multi-dimensional cannabis company focused on its retail customers and technology to democratize cannabis markets
  • Leviathan Natural Products Inc. opened trading at $1.24 per share

Leviathan Natural Products (EPIC) has sold its 100-per-cent interest in Woodstock Biomed Inc. for $5,000,000.

Proceeds from the sale will be used for general corporate purposes and working capital needs.

Woodstock Biomed Inc. operates as a pharmaceutical company with a special focus on the production of medical cannabis for clients who use marijuana for medical treatments across Canada.

Woodstock Biomed owns a 30-acre property with greenhouse infrastructure in Pelham, Ontario, from where it produces its cannabis, mainly supplied to pharmaceuticals and horticulturalists.

In addition, the board of directors of Leviathan has appointed Linda Marabeti Romano as chief financial officer.

Marabeti Romano replaces Manish Z. Kshatriya effective immediately.

Linda Marabeti Romano brings 20 years of work experience in corporate accounting, finance, tax, audit and assurance.

Leviathan Natural Products Inc. is a multi-dimensional cannabis company focused on its retail customers and technology to democratize cannabis markets.

Leviathan Natural Products Inc. opened trading at $1.24 per share.


More From The Market Online

The Market Online’s Weekly Cannabis Report – April 19, 2024

Cannabis news this week: Canopy Growth shareholders overwhelmingly voted to approve a new class of exchangeable shares.

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.